Indivior PLC

29.13+3.89 (+15.4%)

Oct 30, 4:00:00 PM EDT · NasdaqGS · INDV · USD

Upcoming Earnings

Report date

EPS

0.49 (0.46 ~ 0.53)

Revenue

263.20M (252.00M ~ 276.10M)

Key Stats

Market Cap

3.63B

P/E (TTM)

35.96

Basic EPS (TTM)

0.81

Dividend Yield

Recent Filings

10-Q

10/30/25Oct 30, 2025

8-K

10/30/25Oct 30, 2025

8-K

Indivior plans U.S. redomiciliation

10/1/25Oct 1, 2025

Indivior PLC announced on October 1, 2025, its plan to redomicile from the U.K. to Delaware via a court-sanctioned scheme, creating new U.S. parent Indivior Pharmaceuticals, Inc., with shares exchanging one-for-one and trading under INDV on Nasdaq. This move, post its 2023 U.S. listing and 2025 London delisting, aims to boost capital markets presence, streamline governance, and align with U.S. health policy for opioid treatments. Shareholders vote at an early December EGM, targeting late January 2026 effectiveness. Yet risks loom: approvals may falter.

8-K

Indivior initiates restructuring

8/26/25Aug 26, 2025

Indivior launched Phase 1 of its Action Agenda on August 26, 2025, simplifying operations by cutting non-essential activities to boost SUBLOCADE growth in the U.S. This includes headcount reductions, real estate consolidations, and planning costs, totaling $39-$50 million in pre-tax restructuring charges, with $27-$35 million cash, mostly in Q3 2025. The moves aim to drive momentum and accountability. Indivior eyes strategic alternatives for OPVEE and non-U.S. operations, potentially yielding more savings.

8-K

CFO agreement updated

8/22/25Aug 22, 2025

Indivior PLC updated its CFO Ryan Preblick's employment agreement on August 20, 2025, aligning it with current U.S. executive standards while keeping his $558,819 base salary, 60% target bonus, and 400% long-term incentives intact. This routine refresh standardizes terms like non-compete clauses and severance—12 months normally, extending to 24 post-change in control—without altering duties or pay. No business disruption expected.

About

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

CEO

Mr. Joseph J. Ciaffoni

IPO

12/29/2014

Website

https://www.indivior.com

Employees

1,000

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic